HeartMechanical versus Biological Aortic Valve Replacement in Patients Aged 50–70 Years: A Systematic Review and Meta-Analysis

In 120,844 patients aged 50–70, mechanical aortic valve replacement showed 12% better overall survival than bioprosthetic valves (HR 0.88; p=0.001). The tradeoff is real: 60% higher major bleeding risk with mechanical valves versus more than double the reoperation rate with bioprosthetic valves (HR 0.44; p<0.001).

Clinical Considerations

• Survival advantage with mechanical valves (HR 0.88) persists across 30 studies, though 29 were observational, limiting causal inference.
• Stroke rates did not differ significantly between valve types (HR 1.07; p=0.37), removing stroke risk as a primary differentiator in counseling.
• Bioprosthetic valve use is rising in this age group, likely shifting future reinterventions toward older, higher-comorbidity patients less suited for reoperation.
• The absence of contemporary randomized trial data leaves a critical evidence gap as valve technology and transcatheter options continue to evolve.

Practice Applications

• Counsel patients aged 50–70 that mechanical valves carry a survival benefit but require lifelong anticoagulation and its associated bleeding risk.
• Individualize valve selection based on bleeding risk tolerance, anticoagulation adherence capacity, and reoperation candidacy.
• Document shared decision-making discussions explicitly, given divergent international guideline recommendations.
• Monitor bioprosthetic patients for structural valve degeneration, particularly as they age into higher surgical risk categories.

More in TAVR